Invest in Lifescient, Inc.
Long-acting drug delivery technology to treat chronic conditions in pets, replacing daily dosing
Highlights
Our Team
Long-Acting Injectables Offer Freedom From Daily Dosing
As pet owners, you know the worry and hassle of giving your furry friends daily medication. Lifescient is changing that. We're developing innovative, long-acting injectable medications that provide treatment for weeks or even months with a single dose – and we invite you to join us!
Placement of the injectable is quick and easily done in a process similar to the placement of a tracking chip. Medication is released according to prescription and after the treatment course is finished, the injectable is safely absorbed.
What Problem Are We Solving?
- For Pet Owners: Imagine no more struggling to pill your cat or worrying about missing your dog's medication. Lifescient's long-acting injectables mean less stress for you and a more comfortable life for your beloved companion.
- For Veterinary Professionals: Improve treatment compliance, reduce the risk of medication errors, and offer better care for your patients. Our technology allows for more consistent drug delivery and frees up pet owners from demanding dosing schedules.
Advantages of Long-Acting Medications
Lifescient is pioneering the use of long-acting injectables in veterinary medicine. Here’s why it matters:
- Less Frequent Dosing: Instead of daily pills, our injectables provide medication for extended periods. Think of it like a long-lasting flea and tick treatment, but for serious illnesses.
- Improved Pet Comfort: No more forcing pills or dealing with messy liquids. Our injectables are administered quickly and easily, similar to a microchip implant.
- Peace of Mind: Guaranteed medication delivery means better health outcomes for pets.
- Versatile Technology: Our LAIs can be adapted to treat a wide range of conditions in dogs, cats, and even horses, with potential for other animals in the future.
How We Started
Lifescient was founded by Kamalesh Rao, a pharmaceutical development expert with 30 years of experience. Kamalesh was a key contributor to the team that developed a long-acting injectable for managing opioid withdrawal in humans. After this groundbreaking technology received approval, he envisioned its potential to improve animal care.
We have since created several prototypes of long-acting injectables and successfully demonstrated their technical feasibility. In 2023, the FDA granted a fee waiver to support the development of our first product, an LAI designed to relieve pain in dogs with bone cancer.
Motivated by our mission to enhance animal well-being and elevate care, we have built a team of dedicated professionals to support our work. Lifescient stands as a pioneer in drug delivery advancements, focused on improving the quality of healthcare for pets and the quality of life for those who love and care for them.
LS-001: An LAI to Treat Pain in Dogs With Bone Cancer
Pain stemming from bone cancer in dogs is severe and often inadequately managed. Our first product, LS-001, is an LAI developed to manage the pain associated with this condition.
The FDA has granted us a waiver of sponsor fees to support the development of LS-001 based on the product being intended for a Minor Use in a Major Species (MUMS). This waiver will save the company over $1 million in product development costs. Other benefits include eligibility to seek MUMS grants totaling up to $500,000 and seven years of exclusive marketing rights upon approval of the product by the FDA.
The FDA has also accepted our Investigational New Animal Drug application to develop LS-001. The acceptance by the FDA signifies that Lifescient has provided sufficient preclinical data and safety information to justify testing in clinical trials.
We're starting with solutions for critical needs and then expanding to other conditions such as treatments for heart disease in dogs and endocrine disorders in cats – common problems that can be better managed with our technology.
LAI is a Platform Technology
Our strategy leverages our LAI platform to create treatments for chronic conditions in various animal species. We have successfully established and validated the technical feasibility through the development of prototypes for multiple medications.
The Competition
We are primarily focused on niche areas within the veterinary medicine market, addressing conditions often overlooked by larger pharmaceutical companies. What distinguishes us is our commitment to creating products that meet the needs of both pets and their families, giving us a unique advantage in the industry. To our knowledge, we are the only company developing subdermal long-acting injectable technology specifically designed for veterinary medicine.
Growing Market Demand
The pet pharmaceutical industry has consistently demonstrated resilience during economic downturns and is poised for continued growth as the global pet population expands.
In the U.S. alone, an estimated 65 million dogs and 32 million cats suffer from acute and chronic pain caused by cancer and its treatments each year according to Strategic Market Research. Additionally, 12 million new cancer diagnoses occur in pets annually. Lifescient's long-acting injectable (LAI) treatment for bone cancer in dogs has the potential to alleviate pain for both dogs and cats affected by various cancer-related conditions.
Effective pain management is a critical component of cancer care for animals. This market, valued at $1.8 billion today, is projected to grow to $2.5 billion by 2027, according to Strategic Market Research.
Why This is a Great Investment?
- Huge and Growing Market: The veterinary pharmaceutical market is booming, with a projected value of $55.4 billion by 2030. More pet owners are seeking advanced care for their animals, and they're willing to pay for it.
- Underserved Needs: We're focusing on areas where existing treatments are inadequate or difficult to administer, giving us a strong competitive advantage.
- Strong Potential for Growth: Our technology can be expanded to treat many different conditions and animal species, opening up significant opportunities.
- FDA Recognition: The FDA has recognized the importance of our work by granting us a fee waiver, saving us over $1 million in development costs.
- Experienced Team: Lifescient was founded by Kamalesh Rao, a pharmaceutical development expert with a proven track record of bringing innovative long-acting injectables to market.
Go to Market Strategy
Lifescient's GTM strategy aims to establish the company as a leader in long-acting injectables (LAIs) for pets by leveraging its unique technology, focusing on educating veterinarians and pet owners, and forming strategic partnerships. The goal is to maximize market penetration and create strong, sustainable revenue streams through partnerships, licensing deals, and targeted marketing.
What Your Investment Will Support
Lifescient is seeking to raise $2 million via this Community Round. Your investment will help us:
- Finalize the development and manufacturing of our initial products.
- Conduct essential testing to ensure safety and effectiveness.
- Bring our game-changing treatments to the pets who need them.
Join Us in Making a Difference!
By investing in Lifescient, you're not just supporting a business; you're contributing to a future where pets live healthier, happier lives, and pet owners have greater peace of mind. Whether you're a pet owner, a veterinary professional, or simply someone who believes in innovative healthcare, we invite you to be a part of our journey.